MCUJ.F Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.68 |
| 52 Week High | CA$1.17 |
| 52 Week Low | CA$0.58 |
| Beta | 0.87 |
| 11 Month Change | 6.68% |
| 3 Month Change | -15.56% |
| 1 Year Change | -40.24% |
| 33 Year Change | -13.40% |
| 5 Year Change | -81.78% |
| Change since IPO | -97.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| MCUJ.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.6% | 4.0% | 2.2% |
| 1Y | -40.2% | 18.3% | 32.6% |
Return vs Industry: MCUJ.F underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: MCUJ.F underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| MCUJ.F volatility | |
|---|---|
| MCUJ.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MCUJ.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MCUJ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
| MCUJ.F fundamental statistics | |
|---|---|
| Market cap | US$6.72m |
| Earnings (TTM) | -US$1.88m |
| Revenue (TTM) | US$14.97m |
0.4x
P/S Ratio-3.6x
P/E RatioIs MCUJ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCUJ.F income statement (TTM) | |
|---|---|
| Revenue | CA$20.93m |
| Cost of Revenue | CA$8.08m |
| Gross Profit | CA$12.85m |
| Other Expenses | CA$15.48m |
| Earnings | -CA$2.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 61.41% |
| Net Profit Margin | -12.56% |
| Debt/Equity Ratio | 0% |
How did MCUJ.F perform over the long term?
See historical performance and comparison